(A) Short-term (1–4 weeks ahead) and (B) medium-term (1–13 weeks ahead, accounted for the whole 2019–20 winter season) forecast on influenza-associated hospital admission rate sinc... by Yiu-Chung Lau (18713218)

Subjects:

Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

“…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”

Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

“…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”

Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

“…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”

Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy by Yuhao Hao (16938532)

“…The twin and triplet drugs exhibited significantly improved synergy with anti-PD-1 in a CT26 colorectal mouse tumor model. …”

Predictors of coronary hyperemic DPV decrease after percutaneous coronary intervention. by Eisuke Usui (12111855)

Subjects:

Number and percentage of AE patients with detectable Em2+ antibodies at different visits and significance level in binominal test. by Beate Grüner (301524)

Subjects:

Forest plot of the improvement in primary endpoints. by Jin-Min Gu (17915039)

Subjects:

Statistically-significant cytokine changes between the pre-infusion and post-infusion blood draws plot of the mean (dot) and confidence interval (whiskers) for the coefficients of... by Jordan K. Abbott (8934239)

Subjects:

Unconfined Compressive Strength of Improved Red Clay. by Quan Shen (37564)

Subjects:

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”

Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

“…<b><i>Results:</i></b> Mean number of attacks/month significantly decreased (95% credible interval [CrI] excluding 0) from 1.15 preintervention to 0.25 and 0.23, 8 and 14 months within intervention, with mean decreases of −0.89 (95% CrI: −1.21 to −0.58) and −0.92 (95% CrI: −1.22 to −0.60), respectively. …”

Enrichment analysis of genes from the significant MS module. by Lai Jiang (2401513)

Subjects:

Synthesis and Preclinical Evaluation of Novel ^99mTc-Labeled FAPI-46 Derivatives with Significant Tumor Uptake and Improved Tumor-to-Nontarget Ratios by Qing Ruan (349572)

Subjects:

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)